Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The O-antigen of Shigella flexneri serotype 2a is a serotype-specific, highly immunogenic polysaccharide that constitutes the outermost domain of the bacterium’s lipopolysaccharide (LPS) layer[1][2][5]. It consists of a repeating tetrasaccharide unit, typically containing three L-rhamnose residues and one N-acetylglucosamine (GlcNAc), with critical modifications such as glucosylation and O-acetylation defining subtype-specific epitopes[1][2]. The O-antigen is the primary determinant of immune recognition and serotyping for Shigella flexneri, playing a key role in the induction of protective antibody responses as well as resistance to complement-mediated killing[1][2][5]. The structure provides a molecular basis for serotype 2a identification and underpins vaccine strategies, as targeting this antigen can confer serotype-specific immunity[4][6]. The O-antigen also serves as a receptor for certain bacteriophages and can influence virulence by modulating outer membrane stability and host cell invasion mechanisms[1][3]. The high variability and capacity for serotype conversion present both challenges and opportunities in disease control, vaccine design, and diagnostic approaches[5][6].
Antibodies bind to O-antigen, neutralizing bacteria and enhancing opsonization[4] Vaccines elicit O-antigen-specific immune responses, providing serotype-specific protection[4] Polysaccharide-based immunization induces functional antibodies, leading to bacterial killing by complement[6]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on O-antigen of Shigella flexneri serotype 2a.